Myriad Genetics and Abbott Laboratories Collaborate on Clinical Study of Metastatic Breast Cancer Treatment

Strategic Insights -

Myriad Genetics, a leading molecular diagnostic company, has partnered with Abbott Laboratories to conduct a Phase III multi-centre, multi-national clinical study on a novel drug candidate for metastatic breast cancer. This collaboration builds upon a previous agreement for a Phase II study with the same study drug. Under the agreement, Myriad will utilize its BRACAnalysis test to identify germline mutations in the BRCA1 and BRCA2 genes in patients enrolled in the study, providing crucial information for patients and clinicians to make informed decisions.

Key Takeaways:

  • Myriad Genetics and Abbott Laboratories have partnered to conduct a Phase III clinical study on a novel drug candidate for metastatic breast cancer treatment.
  • This agreement is an extension of a previous partnership for a Phase II study with the same study drug.
  • Myriad will use its BRACAnalysis test to identify germline mutations in the BRCA1 and BRCA2 genes in patients enrolled in the study.
  • BRACAnalysis provides important information on the risk of developing breast and ovarian cancer, enabling patients and clinicians to make informed decisions.
  • According to researchers published in the Journal of the National Cancer Institute, pre-symptomatic individuals with high breast cancer risk can reduce their risk by 50% with appropriate preventive therapies.
  • Similarly, researchers published in the New England Journal of Medicine have shown that pre-symptomatic individuals with gene mutations can lower their risk of developing ovarian cancer by 60% with preventive therapies.
  • Myriad Genetics Inc is a leading molecular diagnostic company focusing on developing and marketing novel predictive medicine, personalised medicine, and prognostic medicine products.

Statistics:

  • Women who test positive with the BRACAnalysis test have an 82% risk of developing breast cancer during their lifetime.
  • They also have a 44% risk of developing ovarian cancer.
  • Pre-symptomatic individuals with high breast cancer risk can reduce their risk by 50% with appropriate preventive therapies.
  • Pre-symptomatic individuals with gene mutations can lower their risk of developing ovarian cancer by 60% with preventive therapies.

Sources:

  • Myriad Genetics Inc
  • Abbott Laboratories
  • Journal of the National Cancer Institute
  • New England Journal of Medicine